New developments in the management of advanced melanoma – Role of pembrolizumab

Giuseppina Improta, Isabella Leone, Marco Donia, Stefania Gieri, Giuseppe Pelosi, Filippo Fraggetta

Research output: Contribution to journalArticlepeer-review


Cancer immunotherapy is now recognized to be fundamental in modern oncology, because immune system recruitment may represent a powerful and innovative strategy in cancer therapy. Pembrolizumab, a highly selective humanized monoclonal antibody directly blocking the interaction between programmed cell death-1 expressed by tumor-associated T-cells and its ligand programmed cell death-L1 present on tumor and stromal cells, was recently approved by US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma and disease progression upon ipilimumab and BRAF inhibitor. This review will focus on the clinical development and use of pembrolizumab in the clinical practice and in the management of advanced melanoma.

Original languageEnglish
Pages (from-to)2535-2543
Number of pages9
JournalOncoTargets and Therapy
Publication statusPublished - Sept 14 2015


  • Advanced melanoma
  • Immunotherapy
  • PD-1 inhibitor
  • Pembrolizumab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'New developments in the management of advanced melanoma – Role of pembrolizumab'. Together they form a unique fingerprint.

Cite this